U.S. equity futures are showing a strong rebound this Monday, October 13, 2025, signaling a positive start to the week for the stock market. This premarket surge comes after President Donald Trump adopted a more conciliatory tone regarding trade relations with China over the weekend, easing investor anxieties that had led to a significant market downturn on Friday. The optimistic sentiment is driving futures higher across the board, with particular strength seen in technology and chipmaker stocks.Premarket ...

Earnings Playbook for the Week Ahead Retail investors are preparing for the kick-off of the third-quarter earnings season, with big banks and other top stocks reporting this week. Here’s a look at some retail favorites that individual investors will be watching. FAST stock is moving. See the real-time price action here. Monday, Oct. 13Before Market Open Fastenal Company (NASDAQ:FAST) kicks off the week with its third-quarter earnings report ahead of Monday’s opening bell. Analysts expect the company to repo ...

Earnings season kicks into gear this week with banks and tech stocks taking center stage. This week we have Bank of America (BAC), Taiwan Semiconductor (TSM), JP Morgan (JPM), Wells Fargo (WFC), Citigroup (C), Morgan Stanley (MS), Goldman Sachs (GS), Johnson & Johnson (JNJ) and ASML Holdings (ASML) all reporting in what shapes as a busy and pivotal week for stocks. Before a company reports earnings, implied volatility is usually high because the market is unsure about the outcome of the report. Speculator ...

Core Insights - Johnson & Johnson (J&J) is in discussions to acquire Protagonist Therapeutics, which could enhance their collaboration and significantly increase Protagonist's market value of over $4 billion [1][2] - J&J currently holds 4% of Protagonist's shares and is collaborating on an oral treatment for immune diseases, with exclusive commercialization rights [2] - The acquisition would provide J&J access to rusfertide, a promising drug for polycythaemia vera, developed in partnership with Takeda Pharmaceutical [2] Financial Impact - Protagonist's stock has surged over 70% in 2025 due to positive trial outcomes, and shares have increased more than 450% since its IPO in 2016 [3] - J&J's market capitalization is nearing $460 billion, making the potential acquisition manageable despite its size [3] Strategic Context - J&J is facing competition for its immune-disease drug Stelara and is actively seeking new products to offset sales losses from patent expirations [4] - The company has a history of strategic acquisitions, including a $15 billion purchase of Intra-Cellular Therapies in January 2025 [4] - In 2024, J&J expanded its biotech footprint with an $850 million acquisition of Proteologix, focusing on immune-mediated diseases [5]

强生也重申其产品"安全、不含石棉，也不会导致癌症"，早在2020年就已经在美国停止销售含滑石粉的 婴儿爽身粉，并改用玉米淀粉配方。 据红星新闻等多家媒体报道，关于强生爽身粉致癌的指控有了新的进展。 美国当地时间10月7日，洛杉矶县法院一陪审团裁定，强生须向一名死于间皮瘤的女性的家属支付9.66 亿美元（约合人民币68.8亿元）赔偿金，认定其滑石粉产品致癌，应承担相应责任。 据了解，死者梅·摩尔是美国加利福尼亚州居民，2021年因罕见癌症间皮瘤去世，这种疾病通常与长期 接触石棉有关。其家属同年起诉强生公司，指控其婴儿爽身粉产品含有石棉纤维，导致摩尔患癌。 之后强生全球诉讼事务副总裁埃里克·哈斯在一份邮件声明中表示，公司计划立即提出上诉，并称这一 判决"极端且违宪"。他还指控原告律师在摩尔案中"引用了不应被提交给陪审团的伪科学证据"。 然而关于使用强生爽身粉及其他滑石粉产品后罹患癌症的指控并不在少数。法庭文件显示，强生公司目 前正面临超过6.7万起诉讼，除了一小部分导致间皮瘤之外，大部分指向了卵巢癌。彭博社数据也显 示，强生累计赔偿超65亿美元，已累计支付超过30亿美元。 对于强生而言，从累计支付30亿美元赔偿金 ...

Throughout human history, people have sought the secret to creating lasting wealth. From gold and land to businesses and bonds, countless vehicles have promised financial security and prosperity. Yet one stands above all others in its proven ability to transform ordinary savers into millionaires: the stock market. Specifically, broad-based equity ownership held over long periods of time represents the most powerful wealth-building engine ever created.This isn’t hyperbole or marketing speak. The track record ...

Core Insights - Douglas Lane & Associates disclosed a purchase of 34,948 shares of Johnson & Johnson, valued at approximately $6 million based on average prices during the third quarter [1][2] - The new stake totals 667,373 shares, with a reported market value of $123.7 million at quarter-end [2] - Johnson & Johnson shares were priced at $190.72, reflecting an 18% increase over the past year, outperforming the S&P 500's 12% gain [3] Financial Performance - Johnson & Johnson reported revenue of $90.6 billion and net income of $22.7 billion for the trailing twelve months [4] - The company has a dividend yield of 2.7% [4] - Last quarter, Johnson & Johnson achieved $23.7 billion in sales, marking a nearly 6% year-over-year increase, with net earnings rising 18% to $5.5 billion [8] Business Overview - Johnson & Johnson operates through a diversified portfolio that includes pharmaceuticals, medical devices, and consumer health products, featuring well-known brands such as Tylenol and Neutrogena [9] - The company's business model focuses on research, development, manufacturing, and global distribution of healthcare products across its three core segments [9] - Primary customers include hospitals, healthcare professionals, retailers, wholesalers, and the general public, with a global reach in both prescription and over-the-counter markets [9] Strategic Developments - Douglas Lane & Associates' investment may indicate confidence ahead of Johnson & Johnson's upcoming third-quarter earnings report, with analysts expecting revenue of about $23.7 billion and earnings of $2.77 per share [7] - Johnson & Johnson is reportedly in talks to acquire Protagonist Therapeutics, which could enhance its immunology pipeline, particularly as its leading product, Stelara, faces market share challenges [11]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...

Core Insights - The market is closely monitoring trade policy developments following President Trump's response to China's rare earth export curbs with higher tariffs [1] - A federal government shutdown may delay the release of key economic reports, but corporate earnings from major banks and semiconductor companies are anticipated [1][3] Corporate Earnings - Major financial firms such as JPMorgan Chase, Wells Fargo, Goldman Sachs, and American Express are set to report earnings this week [2][5] - TSMC, the world's largest chip manufacturer, is expected to report a 40% revenue growth in the first half of 2025 due to strong AI chip sales [7] - Other financial institutions reporting include BlackRock, CitiGroup, Bank of America, and Morgan Stanley throughout the week [6] Economic Data and Federal Reserve - The ongoing government shutdown is likely to extend the blackout on economic data releases, affecting reports on retail sales, jobless claims, and housing starts [3][8] - Federal Reserve officials, including Chair Jerome Powell, are scheduled to speak, coinciding with the release of the Beige Book economic update [9] Key Events and Conferences - Oracle's AI World conference begins on Monday, while Salesforce's Dreamforce event starts on Tuesday [7] - The bond market will be closed on Monday for Columbus Day, but major stock exchanges will remain open [4]

IMF更新全球经济展望，美联储公布褐皮书。 上周国际市场风云变幻，关税阴云再起，黄金再迎里程碑。美股全线下挫，道指周跌2.73%，纳指周跌 2.53%，标普500指数周跌2.43%。欧洲三大股指表现不佳，英国富时100指数周跌0.67%，德国DAX 30 指数周跌0.56%，法国CAC 40指数周跌2.02%。 本周看点颇多，市场持续关注美国政府停摆的相关进展以及美联储是否会释放进一步降息的信号。若停 摆持续，更多经济数据可能会延迟发布，此外多位美联储官员将发表例行讲话。在欧洲，通胀数据将影 响未来政策路径走向，英国与澳大利亚将公布关键就业数据。世界银行和国际货币基金组织（IMF）的 秋季年会召开，届时将公布最新经济展望。美股新财报季拉开帷幕，大型银行将率先亮相。 鲍威尔再亮相 美国劳工统计局于上周五证实，原定于下周发布的9月消费者价格指数（CPI）报告，将调整至美国东 部时间10月24日（周五）上午8点30分发布。因联邦预算僵局，美国劳工统计局失去资金支持，员工被 迫离岗。美国劳工统计局在一份声明中指出，9月物价数据将是特例，在政府停摆问题解决前，该局不 会发布其他任何数据。 本周内计划发布但同样可能延迟的 ...